Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U1NA
|
|||
| Former ID |
DIB007892
|
|||
| Drug Name |
Fadolmidine
|
|||
| Synonyms |
Fadolmidine hydrochloride; MPV-2426
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neuropathic pain [ICD-11: 8E43.0] | Phase 2 | [1] | |
| Pain [ICD-11: MG30-MG3Z] | Discontinued in Phase 2 | [2] | ||
| Company |
Orion Corp
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H14N2O
|
|||
| Canonical SMILES |
C1CC2=C(C1CC3=CN=CN3)C=C(C=C2)O
|
|||
| InChI |
1S/C13H14N2O/c16-12-4-3-9-1-2-10(13(9)6-12)5-11-7-14-8-15-11/h3-4,6-8,10,16H,1-2,5H2,(H,14,15)
|
|||
| InChIKey |
VTZPAJGVRWKMAG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 189353-31-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor Alpha-2 (ADRA2) | Target Info | Agonist | [1] |
| Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Agonist | [3] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013220) | |||
| REF 3 | Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist. CNS Drug Rev. 2004 Summer;10(2):117-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.